Trial Profile
A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms VRC 015
- 21 Apr 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jul 2008 New trial record.